The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Vor Bio (VOR) announced on Wednesday that its collaborator, RemeGen Co., achieved the primary goal in a late-stage study in ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...